DFP-17729 / Delta-Fly Pharma - LARVOL DELTA

Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729 (Businesswire) - "We are pleased to announce that as a result of consultation with the PMDA on December 3rd, 2024, the Phase II/III clinical trial of DFP-17729 in combination with TS-1 versus TS-1 alone in patients with pancreatic cancer after third-line treatment was approved."

New P2/3 trial • Pancreatic Cancer

Phase I/II clinical study of DFP-17729 as alkalizing agent in patients with metastatic pancreatic cancer (ESMO-GI 2024) - "We aimed to examine the safety and efficacy of DFP-17729 with chemotherapy in patients with metastatic PC. The study was a multi-center, open-label phase I/II study investigating the combination of DFP-17729 plus gemcitabine (Gem) or S-1 after first-line treatment in patients with metastatic PC... Although the primary endpoint was not met in this study, alkalization of DFP-17729 combined with S-1 shows good potential with survival benefit as third/fourth-line treatment for metastatic PC."

Clinical • Metastases • P1/2 data • Gastrointestinal Cancer • Hepatology • Metabolic Disorders • Oncology • Pancreatic Cancer • Solid Tumor